Navigation Links
CSL Behring Recognized as a "Pioneer" By European Organisation for Rare Diseases (EURORDIS)
Date:3/1/2012

BRUSSELS, March 1, 2012 /PRNewswire/ -- CSL Behring is the recipient of a 2012 EURORDIS Award for its pioneering work in developing and manufacturing therapies used to treat rare and serious medical conditions. The global biotherapeutics company, which specializes in plasma-derived and recombinant therapies used to treat congenital bleeding disorders, immune deficiencies, hereditary angioedema and inherited respiratory disease, is a subsidiary of CSL Limited (ASX:CSL).

(Logo:  http://photos.prnewswire.com/prnh/20100914/PH63692LOGO )

One of the primary criteria for the award is a demonstrated commitment to providing access to therapies for people with rare diseases. The award was presented yesterday at the first EURORDIS Gala Dinner in the Hotel Le Plaza. "Solidarity," the theme of 2012 Rare Disease Day, focuses on the importance and the need for collaboration in the field of rare diseases.

"CSL Behring is honored and delighted to receive a 2012 EURORDIS Award," said Senior Vice President of Public Affairs Dennis Jackman. "This award is a reflection of our commitment to providing safe and effective therapies to improve the lives of patients with rare and serious medical conditions.  CSL Behring's commitment is further demonstrated in the company's growing investment in research and development, which has added to an extensive rare disease product portfolio, and in advanced manufacturing facilities and patient support."

CSL Behring received the National Organization for Rare Disorders 2011 Corporate Award for new treatments for rare diseases brought to market in the U.S.

About EURORDIS

EURORDIS is a non-governmental, patient-driven alliance of patient organisations and individuals active in the field of rare diseases, dedicated to improving the quality of life of all people living with rare diseases in Europe.

About CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the company manufactures and markets a range of plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease. The company's products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic diseases in the newborn.

CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. CSL Behring is a subsidiary of CSL Limited (ASX: CSL), a biopharmaceutical company headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com or view CSL Limited's Corporate Responsibility Report.

Contact:
Chris Florentz
Manager, Corporate Communications
610-878-4316
Christopher.Florentz@cslbehring.com


'/>"/>
SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Screened in CSL Behring Global Phase I/III Study of Recombinant Single-Chain Factor VIII
2. CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
3. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
4. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
5. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
6. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
7. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
8. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
9. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
10. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
11. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the ... (United States, China, Japan, Brazil, United Kingdom, Germany, France, ... Surgical Procedure Volumes: ... provides surgical procedure volume data in a geographic context. ... analysis of growth drivers and inhibitors, including world population ...
(Date:6/23/2016)... The Biotechnology industry might still ... great opportunities to investors. Stock-Callers.com assesses the recent performances ... XON ), Vertex Pharmaceuticals Inc. (NASDAQ: ... ARNA ), and Regeneron Pharmaceuticals Inc. (NASDAQ: ... your complimentary trade alerts at: http://stock-callers.com/registration ...
(Date:6/23/2016)... SAN DIEGO , June 23, 2016 /PRNewswire/ ... advancing programs that address medical conditions resulting from ... that it has appointed Greg Doyle ... member of Leading BioSciences, executive management team and ... officer and chief financial officer. He will provide ...
Breaking Medicine Technology:
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):